Physician profile
Khalid Zafar
NPI 1750363453
$2,535.28
in general payments reported to CMS, 2019-2025
23 companies · $623 in 2025
The $623 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $90.21 · 2021: $330 · 2022: $211 · 2023: $451 · 2024: $694 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $360.78 | 2019-2025 | Ultomiris |
| Travere Therapeutics, INC. | $254.33 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $238.98 | 2021-2025 | Lupkynis |
| Amgen INC. | $229.21 | 2019-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $170.37 | 2019-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $149.33 | 2023-2024 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $145.86 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $145.56 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.69 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $127.39 | 2021-2025 | Benlysta |
| Daiichi Sankyo INC. | $111.87 | 2020-2021 | |
| Ardelyx, INC. | $109.87 | 2023-2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $68.23 | 2020-2025 | Jynarque, Voyxact |
| Mallinckrodt Hospital Products INC. | $62.54 | 2024-2025 | Acthar |
| Vifor Pharma, INC. | $52.28 | 2023 | Veltassa, Korsuva |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $27.98 | 2023 | Accrufer |
| Apellis Pharmaceuticals, INC. | $25.85 | 2025 | Empaveli |
| Boston Scientific Corporation | $22.67 | 2025 | Vtc |
| Mallinckrodt Enterprises LLC | $22.36 | 2019 | |
| Ani Pharmaceuticals, INC. | $21.13 | 2024 | Purified Cortrophin Gel |
| Alnylam Pharmaceuticals INC. | $20.29 | 2023 | Oxlumo |
| Ultragenyx Pharmaceutical INC. | $14.45 | 2021 | |
| Fresenius USA Marketing, INC. | $13.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Zafar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.